rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

James B. Breitmeyer

Director

Company insider

Files Form 4 as: Director, Vaxart; Chief Executive Officer, Oncternal Therapeutics; Director, Otonomy; Director, Zogenix; EVP, Cmo, Cadence Pharmaceuticals.

Every Form 4 they filed

In numbers

Trades disclosed
168
Buys
3
Sells
21
Bought
$86K
Sold
$1.5M
Companies
5
Companies where not an officer
3
First trade
22 Mar 2007
Last trade
16 Jul 2026
Last filed
17 Jul 2026

Companies traded

Where they are an officer
Oncternal TherapeuticsDirector, Officer · last 14 Feb 20243 buys · 0 sells
Cadence PharmaceuticalsOfficer · last 14 Mar 20120 buys · 19 sells
Everywhere else they filed: board seats, 10% stakes, other companies
VaxartDirector · Biotechnology · last 16 Jul 20260 buys · 0 sells
OtonomyDirector · last 21 Jun 20220 buys · 0 sells
ZogenixDirector · last 7 Mar 20220 buys · 2 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
16 Jul 2026filed 17 Jul 2026VaxartBiotechnologySEC FORM 4 Code A—8,315 at $0.00filing
16 Jul 2026filed 17 Jul 2026Vaxartoption or derivative · BiotechnologySEC FORM 4 Code A—16,610 at $0.00filing
16 Jul 2026filed 17 Jul 2026Vaxartoption or derivative · BiotechnologySEC FORM 4 Code A—16,610 at $0.00filing
16 Jul 2026filed 17 Jul 2026VaxartBiotechnologySEC FORM 4 Code A—8,315 at $0.00filing
23 Apr 2026filed 1 May 2026VaxartBiotechnologySEC FORM 4 Code A—78,800 at $0.00filing
23 Apr 2026filed 1 May 2026Vaxartoption or derivative · BiotechnologySEC FORM 4 Code A—157,400 at $0.00filing
23 Apr 2026filed 1 May 2026Vaxartoption or derivative · BiotechnologySEC FORM 4 Code A—157,400 at $0.00filing
23 Apr 2026filed 1 May 2026VaxartBiotechnologySEC FORM 4 Code A—78,800 at $0.00filing
14 Feb 2024filed 15 Feb 2024Oncternal Therapeuticsoption or derivativeSEC FORM 4 Code A—28,400 at $0.00filing
14 Feb 2024filed 15 Feb 2024Oncternal Therapeuticsoption or derivativeSEC FORM 4 Code A—6,200 at $0.00filing
3 Jan 2024filed 5 Jan 2024Oncternal TherapeuticsSEC FORM 4 Code F$25K50,955 at $0.50filing
3 Jan 2024filed 5 Jan 2024Oncternal TherapeuticsSEC FORM 4 Code F$2,2434,485 at $0.50filing
2 Oct 2023filed 4 Oct 2023Oncternal Therapeuticsoption or derivativeSEC FORM 4 Code D—100,000filing
2 Oct 2023filed 4 Oct 2023Oncternal Therapeuticsoption or derivativeSEC FORM 4 Code D—66,890filing
2 Oct 2023filed 4 Oct 2023Oncternal Therapeuticsoption or derivativeSEC FORM 4 Code D—750,000filing
2 Oct 2023filed 4 Oct 2023Oncternal Therapeuticsoption or derivativeSEC FORM 4 Code D—637,000filing
2 Oct 2023filed 4 Oct 2023Oncternal Therapeuticsoption or derivativeSEC FORM 4 Code D—123,750filing
2 Oct 2023filed 4 Oct 2023Oncternal Therapeuticsoption or derivativeSEC FORM 4 Code D—650,000filing
2 Oct 2023filed 4 Oct 2023Oncternal Therapeuticsoption or derivativeSEC FORM 4 Code A—100,000filing
2 Oct 2023filed 4 Oct 2023Oncternal Therapeuticsoption or derivativeSEC FORM 4 Code A—66,890filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Not placed24

Buys in green, sells in red, by the company’s sector.

Related people

Nobody else traded the same names lately.